Company Quick10K Filing
Pfizer
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 5,711 $249,913
10-Q 2019-11-07 Quarter: 2019-09-29
10-Q 2019-08-08 Quarter: 2019-06-30
10-Q 2019-05-09 Quarter: 2019-03-31
10-K 2019-02-28 Annual: 2018-12-31
10-Q 2018-11-08 Quarter: 2018-09-30
10-Q 2018-08-09 Quarter: 2018-07-01
10-Q 2018-05-10 Quarter: 2018-04-01
10-K 2018-02-22 Annual: 2017-12-31
10-Q 2017-11-09 Quarter: 2017-10-01
10-Q 2017-08-10 Quarter: 2017-07-02
10-Q 2017-05-11 Quarter: 2017-04-02
10-K 2017-02-23 Annual: 2016-12-31
10-Q 2016-11-10 Quarter: 2016-10-02
10-Q 2016-08-11 Quarter: 2016-07-03
10-Q 2016-05-12 Quarter: 2016-04-03
10-K 2016-02-29 Annual: 2015-12-31
10-Q 2015-11-05 Quarter: 2015-09-27
10-Q 2015-08-06 Quarter: 2015-06-28
10-Q 2015-05-07 Quarter: 2015-03-29
10-K 2015-02-27 Annual: 2014-12-31
10-Q 2014-11-06 Quarter: 2014-09-28
10-Q 2014-08-07 Quarter: 2014-06-29
10-Q 2014-05-08 Quarter: 2014-03-30
10-K 2014-02-28 Annual: 2013-12-31
10-Q 2013-11-08 Quarter: 2013-09-29
10-Q 2013-08-09 Quarter: 2013-06-30
10-Q 2013-05-10 Quarter: 2013-03-31
10-K 2013-02-28 Annual: 2012-12-31
10-Q 2012-11-09 Quarter: 2012-09-30
10-Q 2012-08-09 Quarter: 2012-07-01
10-Q 2012-05-10 Quarter: 2012-04-01
10-K 2012-02-28 Annual: 2011-12-31
10-Q 2011-11-10 Quarter: 2011-10-02
10-Q 2011-08-11 Quarter: 2011-07-03
10-Q 2011-05-12 Quarter: 2011-04-03
10-K 2011-02-28 Annual: 2010-12-31
10-Q 2010-11-12 Quarter: 2010-10-03
10-Q 2010-08-12 Quarter: 2010-07-04
10-Q 2010-05-13 Quarter: 2010-04-04
10-K 2010-02-26 Annual: 2009-12-31
8-K 2019-12-13 Officers, Exhibits
8-K 2019-10-29 Earnings, Exhibits
8-K 2019-09-24 Officers, Exhibits
8-K 2019-07-31 Regulation FD, Exhibits
8-K 2019-07-29 Earnings, Exhibits
8-K 2019-07-29 Enter Agreement, Regulation FD, Exhibits
8-K 2019-06-27 Officers, Exhibits
8-K 2019-06-14 Regulation FD, Other Events, Exhibits
8-K 2019-04-30 Earnings, Exhibits
8-K 2019-04-25
8-K 2019-03-11 Other Events, Exhibits
8-K 2019-03-04 Other Events, Exhibits
8-K 2019-01-29 Earnings, Exhibits
8-K 2018-12-19 Regulation FD, Exhibits
8-K 2018-12-19 Enter Agreement
8-K 2018-12-07 Other Events
8-K 2018-10-30 Earnings, Exhibits
8-K 2018-09-27 Officers, Exhibits
8-K 2018-09-04 Other Events, Exhibits
8-K 2018-07-31 Earnings, Exhibits
8-K 2018-05-01 Earnings, Exhibits
8-K 2018-04-26
8-K 2018-03-02 Officers, Exhibits
8-K 2018-02-22 Officers, Exhibits
8-K 2018-01-30 Earnings, Exhibits

Pfizer Financials

PFE Metrics, Comps, Filings

Annual | Quarterly

Business

Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world's best-known consumer healthcare products. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Our revenues are derived from the sale of our products and, to a much lesser extent, from alliance agreements, under which we co-promote products discovered or developed by other companies or us. The majority of our revenues come from the manufacture and sale of biopharmaceutical products. The Company was incorporated under the laws of the State of Delaware on June 2, 1942.

We believe that our medicines provide significant value for both healthcare providers and patients, not only from the improved treatment of diseases but also from a reduction in other healthcare costs, such as emergency room or hospitalization costs, as well as improvements in health, wellness and productivity. We continue to actively engage in dialogues about the value of our medicines and how we can best work with patients, physicians and payers to prevent and treat disease and improve outcomes. We continue to work within the current legal and pricing structures, as well as continue to review our pricing arrangements and contracting methods with payers, to maximize patient access and minimize any adverse impact on our revenues. We remain firmly committed to fulfilling our company's purpose: Breakthroughs that change patients' lives. By doing so, we expect to create value for the patients we serve and for our shareholders.

We are committed to capitalizing on growth opportunities by advancing our own pipeline and maximizing the value of our in-line products, as well as through various forms of business development, which can include alliances, licenses, joint ventures, collaborations, equity- or debt-based investments, dispositions, mergers and acquisitions. We view our business development activity as an enabler of our strategies, and we seek to generate earnings growth and enhance shareholder value by pursuing a disciplined, strategic and financial approach to evaluating business development opportunities.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Johnson & Johnson (JNJ) 379,441 67% 14.8 11% 155,117 94,332 81,325 54,220 16,332 26,618 392,764
Pfizer (PFE) 249,913 80% 17.8 8% 156,199 96,274 53,657 42,879 12,674 16,080 286,383
Merck (MRK) 217,623 70% 14.1 11% 83,965 56,330 44,368 31,007 9,370 16,585 233,734
GlaxoSmithKline (GSK) 200,316 0% 58,066 54,394 0 0 0 0 225,704
Novartis (NVS) 197,050 0% 145,563 66,871 0 0 0 0 193,929
Abbott (ABT) 149,087 57% 22.9 4% 68,427 36,741 30,935 17,651 2,895 7,217 164,940
Eli Lilly (LLY) 106,241 77% 11.8 20% 38,666 35,809 23,229 17,810 7,843 9,937 117,668
AbbVie (ABBV) 100,912 77% 18.0 7% 57,142 65,708 32,624 25,254 4,118 7,085 127,359
Beigene (BGNE) 98,573 88% -152.1 -31% 2,150 579 434 383 -664 -642 97,723
Bristol Myers Squibb (BMY) 73,829 53% 8.4 11% 55,163 39,012 23,857 12,640 6,226 8,365 69,858
Celgene (CELG) 67,154 96% 10.4 13% 39,183 29,132 16,354 15,736 5,271 7,702 79,730
GW Pharmaceuticals (GWPH) 64,239 88% -1,554.6 -6% 843 114 114 100 -50 -41 63,656
Allergan (AGN) 54,767 85% 80.8 -4% 123,846 38,273 15,678 13,341 -5,356 939 75,841
Zoetis (ZTS) 54,569 67% 25.9 13% 10,986 8,575 6,046 4,046 1,375 2,291 59,314
Sanofi (SNY) 52,845 0% 111,408 0 0 0 0 52,184
Vertex Pharmaceuticals (VRTX) 46,842 87% 16.9 33% 7,033 1,964 3,454 2,990 2,355 2,569 43,540
Regeneron Pharmaceuticals (REGN) 35,984 0% 15.2 16% 13,174 3,418 7,237 0 2,069 2,295 34,925
Alexion Pharmaceuticals (ALXN) 28,246 71% 15.7 9% 14,568 4,404 4,499 3,191 1,334 1,835 28,827
Biomarin Pharmaceutical (BMRN) 15,774 79% 680.7 -3% 4,393 1,432 1,533 1,213 -110 24 16,336
Elanco Animal Health (ELAN) 12,085 52% 30.6 2% 8,857 3,591 3,073 1,591 144 460 14,098

Balance Sheet ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash1,9781,7353,53910,3892,1833,3433,6412,5951,3421,225
Accounts Receivable14,64514,61213,60812,3789,3578,6698,1768,2258,2218,025
Inventory12,4038,4057,7697,0636,1665,6637,5136,7837,5787,508
PP&E22,78019,12316,93814,46125,67811,76213,76613,31813,86513,385
Assets212,949195,014188,002185,798172,101169,274167,460171,615171,797159,422
Accounts Payable4,3704,0263,8364,2643,2343,4403,6204,5364,6564,674
Long-Term Debt43,22042,30040,10037,50035,10031,54128,81831,39837,08437,685
Liabilities122,503106,749105,381104,12095,48197,652102,463111,776100,14195,664
Stockholders' Equity90,01487,81382,19081,26076,30771,30164,72059,54471,30863,407
Income Statement ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue50,00967,80967,42558,98651,58449,60548,85152,82452,54653,647
Cost of Revenue8,88816,27915,08511,3349,58611,248
Gross Profit41,12151,53052,34047,65241,99842,399
R&D7,8459,4139,1127,8706,6788,3937,6907,8727,6578,006
SG&A14,87519,61419,46816,61614,35514,09714,80914,83714,78414,455
Tax2,1971,1244,0232,5624,3062,1002,3832,521-9,049706
Net Income8,6448,28910,05114,59822,0729,1686,9867,24621,35511,188
Cash Flow ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating16,58711,45420,24017,05417,76516,88314,51215,90116,47015,827
Cash Investing-31,272-4922,2006,154-10,625-5,654-2,980-7,811-4,7414,525
Cash Financing14,481-11,174-20,607-15,999-14,975-9,986-10,233-8,921-13,035-20,441